Empatica Raises Series B Financing

Empatica Raises Series B Financing

Empatica Health Monitoring Platform Empatica Health Monitoring Platform can help accelerate the development of new therapies and digital indicators for patient care and clinical research. The FDA approval also includes data collection for constant monitoring of SpO2 Electrodermal Activity, Skin Temperature, and other sleep-related activities.

Also Read: CatalYm Closes EUR 50M Series C Financing

Empatica Raises Series B Financing

Empatica, a Boston, Massachusetts-based AI and digital health company, raised an undisclosed amount of Series B financing.

It was launched by Sanofi Ventures and RA Capital Management, as well as participation from Black Opal Ventures.

The company plans to use the funds to grow its range of digital biomarkers to be used in the treatment of patients and digital endpoints for clinical studies.

Empatica offers health monitoring powered by AI. Its Empatica Health Monitoring Platform is an internet-based health monitoring solution and data collection for healthcare professionals and researchers built on the data gathered by the CE-certified medical-grade EmbracePlus wearable.

The platform also features a custom Software suite for Care, secure cloud infrastructure, and clinically verified digital biomarkers.

The flagship Medical wearable device, EmbracePlus, has been created with key partners, including HHS, USAMRDC, and the NASA-funded TRISH. Thousands of institutions utilize the platform and the technology for research to study sleep, stress, epilepsy, migraine, depression, addiction, and many other disorders.

It also revealed the approval of their Empatica Health Monitoring Platform by the US Food and Drug Administration (FDA).

Also Read: Afon Technology Raised PS600K in Funding

Chris Evan was born in Dubai and raised in Montreal. He studied Computer Science and was so pleased with computer languages. He began writing after obsessing over technology.

Leave a Reply

Your email address will not be published. Required fields are marked *